Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Biotechnology

Healthcare
$26.62 +0.93%

+$0.14 today

Market cap
$3.42B
Beta
-0.16
P/E (TTM)
-11.3
EPS (TTM)
-$1.36
52W Low $4.80High $18.61

Volume 1.51M

Average 1.21M

AMLX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Amylyx Pharmaceuticals, Inc.NASDAQ: AMLX

Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026

Cost of revenue remains negative

Q3 FY2026 cost of revenue was $0, compared with $19.86M a year earlier. Trailing-twelve-month cost of revenue was $108K. Over 3 fiscal years it compounded at -44.0% a year.

Context

  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $27K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$525K-98.8% YoY
LTMSep 2026
$108K-99.7% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-98.8%——
3-year CAGR-44.0%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
525K USD
Year-over-year change
-98.8%

Cost of Revenue vs competitors

How AMLX compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -99.7% is the lowest of 4, against a peer median of +44.2%.
  • Over three fiscal years its annual growth of -44.0% compares with a peer median of +4.3%.
AMLX Competitors
Cost of Revenue for AMLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$77.55M USD-68.5%-90.3%—
PRTAProthena Corporation plcLTM Mar 2026$30.8M USD——53.2%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$17.04M USD+44.2%+4.3%1.8%
DNLIDenali Therapeutics Inc.LTM Jun 2026$5.8M USD——161.0%
CLNNClene Inc.LTM Mar 2026$378K USD+410.8%+18.3%282.1%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$108K USD-99.7%-44.0%—
ACIUAC Immune S.A.LTM Mar 2026CHF 0 CHF——0.0%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
AVXLAnavex Life Sciences Corp.LTM Dec 2025$0 USD———
PMNProMIS Neurosciences, Inc.LTM Jun 2026$0 USD———
Peer median (excluding AMLX) —+44.2%+4.3%53.2%

Competitors are the stored peer set for AMLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue022.23M380.79M87.37M0
Cost of Revenue02.99M25.44M42.16M525K
Gross Profit019.24M355.35M45.22M(525K)
Gross Margin—86.5%93.3%51.8%—
Research & Development44.04M93.45M128.19M104.08M90.4M
Selling, General & Admin38.93M127.13M188.36M114.33M62.89M
Operating Expenses82.69M220.58M316.54M359.95M152.77M
Depreciation & Amortization52K487K1.09M904K525K
EBITDA(87.88M)(197.11M)55.39M(290.98M)(144.16M)
EBITDA Margin—-886.7%14.5%-333.0%—
Operating Income(82.69M)(201.34M)38.8M(314.73M)(153.29M)
Operating Margin—-905.7%10.2%-360.2%—
Interest Income36K4.29M16.16M13.81M9.3M
Interest Expense00000
Other Income / Expenses(5.24M)3.74M15.5M12.6M8.6M
Income Before Tax(87.93M)(197.6M)54.3M(302.14M)(144.69M)
Pre-Tax Margin—-888.9%14.3%-345.8%—
Income Tax Expense0774K5.03M(393K)46K
Net Income(87.93M)(198.38M)49.27M(301.74M)(144.74M)
Net Margin—-892.4%12.9%-345.4%—
EPS (Basic)(1.52)(2.98)0.73(4.43)(1.53)
EPS (Diluted)(1.52)(2.98)0.70(4.43)(1.53)
Weighted Avg Shares57.86M66.51M67.23M68.14M94.57M
Weighted Avg Shares (Diluted)57.86M66.51M69.99M68.14M94.57M

Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Intrinsic Alpha fair value

Locked

Current Price

$26.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.